NAD+ and cellular energy: the evidence so far

NAD+ is a coenzyme central to how your cells make energy and repair themselves. Levels decline with age, and that decline is where the longevity conversation starts.

What the science supports

Research links NAD+ precursors to mitochondrial function, recovery and cognitive markers. The evidence is promising and still maturing, which is exactly why a monitored, biomarker-guided protocol beats a bottle bought on faith.

Our approach

Quarterly biomarker review, provider oversight, and honest framing of what’s known and what isn’t.

Why biomarkers beat the bathroom scale

Weight is a single number. Your biology is a system. At Welm, progress is measured against biomarkers, not just the scale, because the scale hides as much as it shows.

What we actually track

Metabolic panels, body composition, and how you respond week to week let a provider calibrate your protocol to you. A pound lost isn’t the same as a pound of fat lost, and a plateau on the scale often masks real metabolic change underneath.

Why it matters

When a provider can see the full picture, dose changes become deliberate, not guesswork. That’s the difference between a protocol and a prescription mailed to your door.

Microdosing GLP-1: what titration really means

“Microdose” and “standard” aren’t marketing tiers, they describe how a provider titrates a GLP-1 to balance results against tolerability.

Start low, adjust with data

GLP-1 therapy works best when the dose climbs gradually, guided by how your body responds. Too fast and side effects spike; too slow and progress stalls. The right curve is individual.

The clinical loop

Weekly check-ins and biomarker review let your provider adjust the plan, the part a vending-machine model skips entirely.